Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention

Gianluca Campo, Rita Pavasini, Giampaolo Morciano, Michael A. Lincoff, Michael C. Gibson, Masafumi Kitakaze, Jacob Lonborg, Amrita Ahluwalia, Hideki Ishii, Michael Frenneaux, Michel Ovize, Marcello Galvani, Dan Atar, Borja Ibanez, Giampaolo Cerisano, Simone Biscaglia, Brandon J. Neil, Masanori Asakura, Thomas Engstrom, Daniel A. Jones & 4 others Dana Dawson, Roberto Ferrari, Paolo Pinton, Filippo Ottani

Research output: Contribution to journalArticle

7 Citations (Scopus)
5 Downloads (Pure)

Abstract

Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3], [4], [5], [9], [10], [11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. This article describes data related article titled "Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials" [17].

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalData in brief
Volume14
Early online date18 Jul 2017
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Nicorandil
Metoprolol
Percutaneous Coronary Intervention
Cyclosporine
Reperfusion
Randomized Controlled Trials
Patient Readmission
Mortality
Drug Delivery Systems
Pharmaceutical Preparations
Meta-Analysis
Mitochondria
Heart Failure
Placebos
Morbidity
ST Elevation Myocardial Infarction

Keywords

  • Journal Article
  • Reperfusion injury
  • Myocardial infarction
  • PCI
  • Cyclosporin
  • Nicorandil
  • Follow-up

Cite this

Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. / Campo, Gianluca; Pavasini, Rita; Morciano, Giampaolo; Lincoff, Michael A.; Gibson, Michael C.; Kitakaze, Masafumi; Lonborg, Jacob; Ahluwalia, Amrita; Ishii, Hideki; Frenneaux, Michael; Ovize, Michel; Galvani, Marcello; Atar, Dan; Ibanez, Borja; Cerisano, Giampaolo; Biscaglia, Simone; Neil, Brandon J.; Asakura, Masanori; Engstrom, Thomas; Jones, Daniel A.; Dawson, Dana; Ferrari, Roberto; Pinton, Paolo; Ottani, Filippo.

In: Data in brief, Vol. 14, 10.2017, p. 197-205.

Research output: Contribution to journalArticle

Campo, G, Pavasini, R, Morciano, G, Lincoff, MA, Gibson, MC, Kitakaze, M, Lonborg, J, Ahluwalia, A, Ishii, H, Frenneaux, M, Ovize, M, Galvani, M, Atar, D, Ibanez, B, Cerisano, G, Biscaglia, S, Neil, BJ, Asakura, M, Engstrom, T, Jones, DA, Dawson, D, Ferrari, R, Pinton, P & Ottani, F 2017, 'Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention', Data in brief, vol. 14, pp. 197-205. https://doi.org/10.1016/j.dib.2017.07.033
Campo, Gianluca ; Pavasini, Rita ; Morciano, Giampaolo ; Lincoff, Michael A. ; Gibson, Michael C. ; Kitakaze, Masafumi ; Lonborg, Jacob ; Ahluwalia, Amrita ; Ishii, Hideki ; Frenneaux, Michael ; Ovize, Michel ; Galvani, Marcello ; Atar, Dan ; Ibanez, Borja ; Cerisano, Giampaolo ; Biscaglia, Simone ; Neil, Brandon J. ; Asakura, Masanori ; Engstrom, Thomas ; Jones, Daniel A. ; Dawson, Dana ; Ferrari, Roberto ; Pinton, Paolo ; Ottani, Filippo. / Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. In: Data in brief. 2017 ; Vol. 14. pp. 197-205.
@article{55d0da7978874f2fa63562a1b841aaf1,
title = "Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention",
abstract = "Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3], [4], [5], [9], [10], [11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. This article describes data related article titled {"}Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials{"} [17].",
keywords = "Journal Article, Reperfusion injury, Myocardial infarction, PCI, Cyclosporin, Nicorandil, Follow-up",
author = "Gianluca Campo and Rita Pavasini and Giampaolo Morciano and Lincoff, {Michael A.} and Gibson, {Michael C.} and Masafumi Kitakaze and Jacob Lonborg and Amrita Ahluwalia and Hideki Ishii and Michael Frenneaux and Michel Ovize and Marcello Galvani and Dan Atar and Borja Ibanez and Giampaolo Cerisano and Simone Biscaglia and Neil, {Brandon J.} and Masanori Asakura and Thomas Engstrom and Jones, {Daniel A.} and Dana Dawson and Roberto Ferrari and Paolo Pinton and Filippo Ottani",
note = "Acknowledgements Conflict of interest: Lincoff receives research support from Kai Pharmaceuticals; Gibson receives research support from Stealth pharmaceuticals; other authors do not declare conflict of interest. Funding: none. Transparency document. Supplementary material Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2017.07.033.",
year = "2017",
month = "10",
doi = "10.1016/j.dib.2017.07.033",
language = "English",
volume = "14",
pages = "197--205",
journal = "Data in brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention

AU - Campo, Gianluca

AU - Pavasini, Rita

AU - Morciano, Giampaolo

AU - Lincoff, Michael A.

AU - Gibson, Michael C.

AU - Kitakaze, Masafumi

AU - Lonborg, Jacob

AU - Ahluwalia, Amrita

AU - Ishii, Hideki

AU - Frenneaux, Michael

AU - Ovize, Michel

AU - Galvani, Marcello

AU - Atar, Dan

AU - Ibanez, Borja

AU - Cerisano, Giampaolo

AU - Biscaglia, Simone

AU - Neil, Brandon J.

AU - Asakura, Masanori

AU - Engstrom, Thomas

AU - Jones, Daniel A.

AU - Dawson, Dana

AU - Ferrari, Roberto

AU - Pinton, Paolo

AU - Ottani, Filippo

N1 - Acknowledgements Conflict of interest: Lincoff receives research support from Kai Pharmaceuticals; Gibson receives research support from Stealth pharmaceuticals; other authors do not declare conflict of interest. Funding: none. Transparency document. Supplementary material Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2017.07.033.

PY - 2017/10

Y1 - 2017/10

N2 - Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3], [4], [5], [9], [10], [11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. This article describes data related article titled "Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials" [17].

AB - Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3], [4], [5], [9], [10], [11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. This article describes data related article titled "Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials" [17].

KW - Journal Article

KW - Reperfusion injury

KW - Myocardial infarction

KW - PCI

KW - Cyclosporin

KW - Nicorandil

KW - Follow-up

U2 - 10.1016/j.dib.2017.07.033

DO - 10.1016/j.dib.2017.07.033

M3 - Article

VL - 14

SP - 197

EP - 205

JO - Data in brief

JF - Data in brief

SN - 2352-3409

ER -